T cell modification and use thereof

A method of treating cancer using immunotherapy, comprising administering to a patient having cancer a population of modified T cells comprising a nucleic acid construct, wherein the cancer expresses one or more tumor antigens selected from NY-ESO1, PRAME, alpha-fetoprotein (AFP), MAGE A4, MAGE A1, MAGE A10 and MAGE B2;

• and wherein the nucleic acid construct comprises:
• (i) a first nucleotide sequence encoding IL 7,
• (ii) a second nucleotide sequence encoding an antigen receptor, wherein the antigen receptor is a chimeric antigen receptor (CAR) that binds to said one or more tumor antigens, or a T cell receptor (TCR) that binds to an MHC-displayed peptide fragment of said one or more tumor antigens;
• (iii) an inducible promoter operably linked to the first nucleotide sequence;
• and
• (iv) a constitutive promoter operably linked to the second nucleotide sequence wherein the administration of said modified T cells results in the treatment of the patient's cancer.